The APHINITY study’s ten-year follow-up results showed that adjuvant Perjeta® (pertuzumab) added to chemotherapy and Herceptin® (trastuzumab) resulted in a clinically significant survival benefit.
One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
The gadget analyzes images using artificial intelligence to achieve a degree of diagnosis accuracy that is not achievable with conventional manual grading techniques.
CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.
Columvi therapy provides a much-needed, off-the-shelf, fixed-duration alternative for transplant ineligible individuals.
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
